EOLS News & Events

Evolus files $250M mixed securities shelf

Evolus announced that the commercial launch of Estyme, its injectable hyaluronic acid gel collection in Europe, is scheduled for May 16th, marking the company's entry into the international dermal filler market. The Estyme collection includes four injectable HA gels that will cover a wide range of applications. The collection includes Estyme Smooth and Estyme Form, which are currently marketed in the United States under the brand Evolysse, along with the debut of two products including Estyme Lips and the flagship product in the line, Estyme Sculpt, which is expecting U.S. FDA approval later this year. Developed for restoring mid-face volume, Estyme Sculpt addresses one of the most in-demand treatment areas in aesthetics. Designed by Symatese, the innovative Cold-X technology helps preserve the natural structure of the HA molecule, providing long-lasting, natural-looking results. The commercial launch follows the successful CE Mark certification under the European Medical Device Regulation.

Reports Q1 revenue $73.1M, consensus $72.17M. "We started 2026 with a second consecutive quarter of positive Adjusted EBITDA, delivering profitability in what is seasonally our lowest revenue quarter," said David Moatazedi, President and Chief Executive Officer of Evolus. "This performance reflects continued strength of the business and the benefit from structural improvements we implemented in 2025. Importantly, achieving profitability in the first quarter further reinforces the durability of our operating model and our confidence in achieving full-year profitability in 2026."